Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Privigen in Systemic Sclerosis
NCT01785056Phase 2Unknown
- Sponsor
- Georgetown University
- Start
- Apr 2013
- Primary completion
- Jan 2018
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in systemic sclerosis (SSc) comparing Privigen with Placebo (2 arms). Primary endpoint: Effects of IVIG on the skin (mRSS) at 4 months. Status: unknown.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT01785056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01785056.